An experimental compound identified by researchers at UC Berkeley could open a different route in the search for more effective weight-loss treatments. Rather than reducing appetite, the compound appears to push the body to burn more energy. In mouse studies, it increased energy expenditure by as much as 18%, supported weight reduction and did so without significant loss of muscle, a key concern in modern obesity care.
The findings matter because the current wave of anti-obesity medicines, including Ozempic and Wegovy, is built largely around GLP-1 pathways that influence appetite and food intake. These medicines have changed the treatment landscape, but weight reduction can also involve the loss of lean mass. A therapy that encourages energy use while helping preserve muscle would address a central challenge for patients and clinicians managing obesity and related metabolic risks.
In the reported experiments, mice receiving the compound showed improved blood sugar control and reduced fat accumulation in the liver, in addition to weight loss. Those outcomes point to effects beyond body weight alone, touching on metabolic health markers often linked to excess weight. The results remain preclinical, and evidence in mice does not establish that the same benefits will occur in humans. Further testing would be required to assess safety, dosing and durability of the effect.
The compound also produced stronger results when used alongside existing GLP-1 medicines than when either approach was used alone. That suggests a possible complementary mechanism: one treatment reduces intake, while the other increases energy expenditure. If confirmed in later research, such a combination strategy could broaden the tools available for treating obesity, diabetes-related metabolic problems and fatty liver conditions without relying on a single biological pathway.
For now, the discovery is best understood as an early scientific signal rather than a near-term therapy. Its significance lies in the direction it points: weight-loss research is moving beyond appetite suppression toward interventions that may reshape how the body uses energy. The ability to reduce fat while sparing muscle would represent an important goal for the next generation of metabolic treatments, but the compound’s clinical potential will depend on results from future studies beyond the laboratory setting.





